The future of engineered immune cell therapies-Reference-Cited by-同舟云学术

The future of engineered immune cell therapies

Published:2022-11-25 Issue:6622 Volume:378 Page:853-858
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Irvine Darrell J.¹²³⁴⁵^ORCID,Maus Marcela V.²⁶⁷^ORCID,Mooney David J.⁸⁹^ORCID,Wong Wilson W.¹⁰^ORCID

Affiliation:

1. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.

2. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

3. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.

4. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.

5. Howard Hughes Medical Institute, Cambridge, MA, USA.

6. Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

7. Harvard Medical School, Boston MA, USA.

8. John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.

9. Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

10. Department of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.

Abstract

Immune cells are being engineered to recognize and respond to disease states, acting as a “living drug” when transferred into patients. Therapies based on engineered immune cells are now a clinical reality, with multiple engineered T cell therapies approved for treatment of hematologic malignancies. Ongoing preclinical and clinical studies are testing diverse strategies to modify the fate and function of immune cells for applications in cancer, infectious disease, and beyond. Here, we discuss current progress in treating human disease with immune cell therapeutics, emerging strategies for immune cell engineering, and challenges facing the field, with a particular emphasis on the treatment of cancer, where the most effort has been applied to date.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference72 articles.

1. The Emerging Landscape of Immune Cell Therapies

2. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

3. Treg cell-based therapies: challenges and perspectives

4. Therapeutic T cell engineering

5. Engineered cellular immunotherapies in cancer and beyond

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors;Biomaterials;2025-01

2. Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation;Nanomedicine: Nanotechnology, Biology and Medicine;2024-11

3. State of the Art on CAR T-Cell Therapies for Onco-Haematological Disorders and Other Conditions;Onco;2024-09-08

4. Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis;Current Research in Translational Medicine;2024-09

5. Bottom-up synthetic immunology;Nature Nanotechnology;2024-08-26